A few studies have examined the methylation status of individual tumor-suppressor genes in CML, with results ranging from rare or no hypermethylation (e.g., SFRP1, RASSF1A) [18], [19] to hypermethylation at progression (e.g., CALCA, CDKN2B, EBF2, ESR, HIC1, TFAP2A, and others) [11], [12], [13], [20]. The gene discussed is CDKN2B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.